

For: **METHODS FOR DETECTING AND ASSAYING
NUCLEIC ACID SEQUENCES**

By: Robert C. Getts
James M. Kadushin

**METHODS FOR DETECTING AND ASSAYING
NUCLEIC ACID SEQUENCES**

Related Application

5

The present Application claims the priority of U.S. Provisional Application Serial Number 60/219,397, filed July 19, 2000, which is fully incorporated herein by reference.

10

Field of the Invention

The present invention is related generally to nucleic acid assays, more particularly to methods for detecting and assaying nucleic acid sequences by hybridization.

15

Background of the Invention

Changes in gene expression patterns or in a DNA sequence can have profound effects on biological functions. Such variations in gene expression may 20 result in altered physiological and pathological processes. Developing DNA technologies are providing rapid and cost-effective methods for identifying gene expression and genetic variations on a large-scale level. One useful development is the DNA microarray useful for rapidly detecting and assaying samples of nucleic acid sequences. Each microarray is capable of performing the equivalent of thousands of

individual “test tube” experiments over a short time period thereby providing rapid and simultaneous detection of thousands of expressed genes. Microarrays have been implemented in a range of applications such as analyzing a sample for the presence of gene variations or mutations (i.e. genotyping), or for patterns of gene expression.

Generally, a microarray comprises a substantially planar substrate such as a glass cover slide, a silicon plate or nylon membrane, coated with a grid of tiny spots or features of about 20 microns or smaller in diameter. Each spot or feature contains millions of copies of a specific sequence of nucleic acid extracted from a strand of deoxyribonucleic acid (DNA). Due to the number of features involved, a computer is typically used to keep track of each sequence located at each predetermined feature. Messenger RNA (mRNA) is extracted from a sample of cells. The mRNA serving as a template, is reverse transcribed to yield complementary DNA (cDNA). As a first example of the prior art techniques, one or more labels or markers such as fluorescence are directly incorporated into the copies of cDNA during the reverse transcription process. The labeled copies of cDNA are broken up into short fragments and washed over the microarray. Under suitable hybridization conditions, the labeled fragments are hybridized or annealed with complementary nucleic acid sequences (i.e. gene probes) attached to the features of the microarray for ready detection thereof. This labeling method has been commonly referred to as “direct incorporation”.

Upon hybridization of the cDNA to the microarray, a detectable signal (e.g. fluorescence) is emitted for a positive outcome from each feature containing a cDNA fragment hybridized with a complementary nucleic acid sequence attached thereto. The detectable signal is visible to an appropriate sensor device or microscope, and 5 may then be detected by the computer or user to generate a hybridization pattern. Since the nucleic acid sequence at each feature is known, any positive outcome (i.e. signal generation) at a particular feature indicates the presence of the complementary cDNA sequence in the sample cell. Although there are occasional mismatches, the attachment of millions of gene probes at each spot or feature 10 ensures that the detectable signal is strongly emitted only if the complementary cDNA of the test sample is present.

A second example of a prior art method of preparing a nucleic acid sequence sample for detection and assay by a microarray is shown in Figure 1 and described 15 as follows. Using known methods, a plurality of gene probes consisting of known nucleic acid sequences are each affixed or printed at a predetermined location on the surface of a microarray. The attachment of the gene probe to the microarray is typically accomplished through known robotic or laser lithographic processes. The sample is extracted from cells in the form of RNA. Since RNA is relatively unstable 20 and decomposes rapidly and easily, a more stable and resistant form of nucleic acid is typically used. The stable nucleic acid is complementary DNA which is prepared from the RNA sample (e.g. total RNA and poly(A)+ RNA) through known techniques of reverse transcription. Reverse transcription primers (RT primers) having a capture sequence attached thereto, is used in reverse transcription process. As a

result, the target cDNA is formed with the capture sequence located at the 5' end. The newly formed target cDNA with the capture sequence is then isolated from the mRNA sample and precipitated. The target cDNA is hybridized to the complementary gene probes affixed to the microarray. After the target cDNA and 5 the microarray are hybridized, the microarray is washed to remove any excess RT primers prior to labeling. A mixture containing labeled "dendritic nucleic acid molecules", or "dendrimers", is then prepared.

Dendrimers are complex, highly branched molecules, and are comprised of a 10 plurality of interconnected natural or synthetic monomeric subunits of double-stranded DNA forming into stable spherical-like core structures with a predetermined number of "free ends" or "arms" extending therefrom. Dendrimers provide efficient means for labeling reactions such as fluorescence, for example, and facilitate direct 15 calculations of the number of transcripts bound due to their predetermined signal generation intensity and proportional relationship to the bound cDNA on the microarray.

Each dendrimer includes two kinds of hybridization "free ends" or "arms" extending from the core surface. Each dendrimer may be configured to include at 20 least one hundred arms of each kind. The arms are each composed of a single-stranded DNA of a specific sequence that can be ligated or hybridized to a functional molecule such as a target or a label. The target molecule can be attached to one kind of arm to provide the dendrimer with targeting capabilities, and the label molecule can be attached to the other kind of arm to provide the dendrimer with

signal emission capabilities for detection thereof. The targeting molecule is typically an oligonucleotide that is complementary to the capture sequence of a target, and the label molecule is typically an oligonucleotide linked to a label or marker. Using simple DNA labeling, hybridization, and ligation reactions, a dendrimer may be 5 configured to act as a highly labeled, target specific probe. Dendrimers are described in greater detail in Nilsen et al., *Dendritic Nucleic Acid Structures*, J. Theor. Biol., 187, 273-284 (1997); and Stears et al., *A Novel, Sensitive Detection System for High-Density Microarrays Using Dendrimer Technology*, Physiol. Genomics, 3: 93-99 (2000), the entire content of each are incorporated herein by 10 reference.

The prepared mixture is formulated in the presence of a suitable buffer to yield a dendrimer hybridization mixture containing dendrimers with labels attached to one kind of arm, and with oligonucleotides complementary to the capture sequences 15 of the cDNA attached to the other type of arm. The labeled dendrimers are added to the microarray for hybridization with the capture sequences of the bound cDNA to generate a detectable signal from the corresponding feature. The microarray is washed to remove any excess unhybridized dendrimer molecules to reduce unwanted noise generation. The microarray is scanned using conventional 20 techniques to detect the detectable signal emitted by the labels to generate a particular hybridization pattern for analysis. It is known that the above-described prior art methods require significant time, effort and labor in the preparation and assay of the sample including the hybridization and washing steps.

It would be highly desirable to substantially reduce the amount of time and the number of steps required for preparing a sample and performing the assay without sacrificing desirable attributes such as sensitivity, low background "noise", and minimal "false positives". It would be a significant advance in gene expression

5 detection microarrays to further provide a method that significantly reduces the complexity and the labor needed to prepare the gene samples and does not require RNA extracted directly from a sample to be converted to cDNA prior to hybridization, but rather uses the RNA sample directly in the methods of the present invention for gene expression analysis, and which can be carried out using conventional

10 laboratory reagents, equipment and techniques.

Summary of the Invention

The present invention relates generally to methods for assaying and detecting the presence of a specific sequence of nucleotides in a nucleic acid target molecule of a sample through the process of hybridization and does not require the time- and labor- consuming enzymatic conversion of that sample into a complementary copy. The present invention significantly reduces the time and labor that are typically required to process and assay the nucleic acid target molecule for obtaining information about the genetic profile of the target nucleic acid sample and the source from which the sample was obtained. The present invention further provides a microarray with excellent sensitivity and low background "noise", and minimal "false positives". The method of the present invention may be used in a range of genomic

applications such as gene expression profiling and high-throughput functional genomic analysis.

The present invention is directed to method for determining the presence of a
5 specific nucleotide sequence in an RNA reagent of a target sample. In a particular
aspect of the invention, the method comprises the steps of:

a) incubating a mixture comprising:

(i) a first component including an RNA reagent extracted directly from
a target sample, said RNA reagent having a target nucleotide sequence and a
10 capture sequence, and

(ii) a second component comprising a capture reagent having at least
one first arm containing a label capable of emitting a detectable signal and at
least one second arm having a nucleotide sequence complementary to the
capture sequence of the RNA reagent of the first component,

15 at a first temperature and for a time sufficient to induce the capture sequence of the
RNA reagent of the first component to bind to the complementary nucleotide
sequence of the capture reagent of the second component, and thereby form a pre-
hybridized RNA-capture reagent complex comprising the target nucleotide
sequence;

20 b) contacting the pre-hybridized RNA-capture reagent complex with a
microarray having thereon a plurality of features each containing a particular probe
nucleotide sequence; and

c) incubating the pre-hybridized RNA-capture reagent complex on the
microarray at a second temperature and for a time sufficient to hybridize the target

nucleotide sequence of the pre-hybridized RNA-capture reagent complex to the complementary probe nucleotide sequence contained within the feature, wherein the presence of such hybridization results in the emission of the detectable signal from the corresponding feature, and the absence thereof results in no emission of the 5 detectable signal from the corresponding feature, thus generating a detectable hybridization pattern for subsequent analysis.

In another aspect of the present invention, there is provided a method for determining the presence of a specific nucleotide sequence in an RNA reagent of a 10 target sample, the method comprising the steps of:

a) contacting a first component including an RNA reagent extracted directly from a target sample, said RNA reagent having a target nucleotide sequence and a capture sequence with a microarray having thereon a plurality of features each containing a particular probe nucleotide sequence;

15 b) incubating the RNA reagent and the complementary probe nucleotide sequences on the microarray at a first temperature and for a time sufficient to hybridize the target nucleotide sequence of the RNA reagent to the complementary probe nucleotide sequence contained within the feature;

c) contacting a second component comprising a capture reagent having 20 at least one first arm containing a label capable of emitting a detectable signal and at least one second arm having a nucleotide sequence complementary to the capture sequence of the RNA reagent of the first component; and

d) incubating the capture reagent and the capture sequence of the RNA reagent at a second temperature and for a time sufficient to induce the capture

sequence of the RNA reagent of the first component to hybridize to the complementary nucleotide sequence of the capture reagent of the second component, wherein the presence of the hybridization results in the emission of the detectable signal from the corresponding feature, and the absence thereof results in 5 no emission of the detectable signal from the corresponding feature, thus generating a detectable hybridization pattern for subsequent analysis.

In a preferred form of the invention the preferred capture reagent is a dendrimer.

10

Brief Description of the Drawings

The following drawings in which like reference characters indicate like parts are illustrative of embodiments of the invention and are not to be construed as 15 limiting the invention as encompassed by the claims forming part of the application.

Figure 1 is a schematic representation of prior art steps for preparing and assaying a target nucleic acid sample on a microarray; and

20

Figure 2 is a schematic representation of a method for preparing and assaying a target nucleic acid sample on a microarray in one embodiment of the present invention.

Detailed Description of the Invention

The present invention is generally directed to a method for preparing a nucleic acid sequence sample for detection and assay on a microarray in a manner that

5 provides a significant reduction in time and effort typically required in assaying a genomic sample on a microarray. The method of the present invention provides the advantage of preparing the nucleic acid sequence sample in shorter period of time, using fewer steps but providing the sensitivity, low background "noise", and minimal "false positives" required for laboratory and clinical use. The cost effective and

10 efficient manner by which the nucleic acid sequence samples are prepared and by which the method of the present invention can be implemented using conventional laboratory techniques, equipment and reagents, makes the present invention especially suitable for use in genomic applications such as gene expression profiling and high-throughput functional genomic analysis.

15

Before the present invention is further described, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology

20 employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.

In the methods of the present invention, an array of DNA or gene probes fixed or stably associated with the surface of a substantially planar substrate is prepared as conventionally known in the art. A variety of different microarrays that may be used are known in the art. The substrates with which the gene probes are stably 5 associated may be fabricated from a variety of materials, including plastic, ceramic, metal, gel, membrane, glass, and the like. The microarrays may be produced according to any convenient methodology, such as pre-forming the gene probes and then stably associating them with the surface of the support or growing the gene probes directly on the support. A number of different microarray configurations and 10 methods for their production are known to those of skill in the art, as described, for example, in Science, 283, 83, 1999, the content of which is incorporated herein by reference.

The DNA or gene probes of the microarrays which are capable of sequence 15 specific hybridization with a target nucleic acid sequence extracted from a target sample of cells, may be comprised of polynucleotides or hybridizing analogues or mimetics thereof, including, but not limited to, nucleic acid in which the phosphodiester linkage has been replaced with a substitute linkage group, such as phosphorothioate, methylimino, methylphosphonate, phosphoramidate, guanidine 20 and the like, nucleic acid in which the ribose subunit has been substituted, e.g. hexose phosphodiester; peptide nucleic acid, and the like. The length of the probes will generally range from 10 to 1000 nucleotides. In the preferred embodiment, the DNA or gene probes are each arranged or sequenced for hybridization with the

target nucleic acid sequence comprising RNA, more preferably mRNA from the gene of concern.

In some embodiments of the invention, the probes will be oligonucleotides
5 having from 15 to 150 nucleotides and more usually from 15 to 100 nucleotides. In other embodiments the probes will be longer, usually ranging in length from 150 to 1000 nucleotides, where the polynucleotide probes may be single or double stranded, usually single stranded, and may be PCR fragments amplified from cDNA, cloned genes, or other suitable sources of nucleic acid sequences. The DNA or
10 gene probes on the surface of the substrates will preferably correspond to, but are not limited to, known genes of the physiological source being analyzed and be positioned on the microarray at a known location so that positive hybridization events may be correlated to expression of a particular gene in the physiological source from which the target nucleic acid sample is derived. Because of the manner in which the
15 target nucleic acid sample is generated, as described below, the microarrays of gene probes will generally have sequences that are complementary to the RNA strands, including but not limited to, messenger RNA strands, of the gene to which they correspond.

20 The term "label" is used herein in a broad sense to refer to agents that are capable of providing a detectable signal, either directly or through interaction with one or more additional members of a signal producing system. Labels that are directly detectable and may find use in the present invention include, for example, fluorescent labels such as fluorescein, rhodamine, BODIPY, cyanine dyes (e.g. from

Amersham Pharmacia), Alexa dyes (e.g. from Molecular Probes, Inc.), fluorescent dye phosphoramidites, and the like; and radioactive isotopes, such as ^{32}S , ^{32}P , ^3H , etc.; and the like. Examples of labels that provide a detectable signal through interaction with one or more additional members of a signal producing system 5 include capture moieties that specifically bind to complementary binding pair members, where the complementary binding pair members comprise a directly detectable label moiety, such as a fluorescent moiety as described above. The label is one that preferably does not provide a variable signal, but instead provides a constant and reproducible signal over a given period of time.

10

The present invention further utilizes a capture reagent which is composed of at least one first arm containing a label capable of emitting a detectable signal and at least one second arm having a nucleotide sequence complementary to a capture sequence attached to the target nucleic acid such as RNA, for example. One such 15 example is a “dendritic nucleic acid molecule”, or “dendrimer”. Briefly, dendrimers are complex, highly branched molecules, and are comprised of a plurality of interconnected natural or synthetic monomeric subunits of double-stranded DNA forming into stable, spherical-like core structures with a pre-determined number of “arms” or “free ends” extending therefrom for the purposes described herein. 20 Typically, the capture reagent will have multiple, typically many first and second arms. Besides dendrimers, carbohydrates, proteins, nucleic acids, and the like may be used as the capture reagent. Dendrimers will be described hereinafter as illustrative of suitable capture reagents.

Each dendrimer may be configured to include two kinds of hybridization “free ends” or “arms” extending from the core surface. Each dendrimer may be configured to include at least one hundred arms of each kind. The arms are each composed of a single-stranded DNA of a specific sequence that can be ligated or hybridized to a functional molecule such as a target or a label. The target molecule can be attached to one kind of arm to provide the dendrimer with targeting capabilities, and the label molecule can be attached to the other kind of arm to provide the dendrimer with signal generation capabilities for detection. The targeting molecule is typically an oligonucleotide that is complementary to the target nucleic acid sequence, and the label molecule is typically an oligonucleotide linked to a label or marker. Using simple DNA labeling, hybridization, and ligation reactions, a dendrimer may be configured to act as a highly labeled, target specific probe molecule.

Further information regarding the structure, configuration and production of dendrimers is also disclosed in U.S. Pat. Nos. 5,175,270, 5,484,904, and 5,487,973, the contents of each are incorporated herein by reference.

In accordance with one embodiment of the present invention, a target nucleic acid, preferably in the form of RNA, and extracted directly from a sample, is contacted with the DNA microarray under conditions sufficient to induce hybridization therebetween, resulting in a hybridization pattern of complementary gene probe/target complexes. Prior to or following the hybridization of the target nucleic acid and the microarray, labeled capture reagents (e.g. dendrimers) under suitable conditions are bonded to the target nucleic acid, whereupon a detectable signal may

generated to subsequently render the particular hybridization pattern visible. It is noted that the hybridizations between the target nucleic acids and the microarray, and between the target nucleic acid and the capture reagent (e.g. dendrimer) may be carried out in any suitable order. The labeled capture reagents (e.g. dendrimers) are 5 each capable of generating the same signal of known intensity, thus each positive signal in the microarray can be "counted" in order to obtain quantitative information about the genetic profile of the target nucleic acid sample.

In one embodiment of the present invention, fluorescent labeled dendrimers 10 may be prepared by ligating a nucleic acid sequence or strand complementary to the capture sequence of a target nucleic acid, preferably polydeoxyribothymidine (poly dT), to the purified dendritic core material as prepared by the previously described methods (see Nilson et al., and Stears et al., *supra*; and the '270, '904, and '973 patent citations mentioned previously). Labeled dendrimers ligated with the poly dT, 15 are able to target and hybridize with a target nucleic acid such as polyadenylated RNA (poly(A)+ RNA), having a capture sequence composed of polydeoxyriboadenidine (poly dA).

As mentioned above, the preferred target nucleic acid is RNA. RNA has 20 rarely been used directly as target nucleic acid samples in the prior art genomic assays due to poor performance results. RNA has an undesirable tendency to decompose rapidly and easily and conventional labeling methods fail to generate adequate signal when used in conjunction with RNA. By utilizing capture reagents (e.g. dendrimers) and the methods of the present invention, the amount of time and

the number of steps required to carry out the genomic assays is reduced, thus enabling the use of RNA at least substantially without the degree of RNA degradation and decomposition typically associated with prior art genomic assays. Furthermore, the direct use of RNA precludes the need to reverse transcribe the 5 RNA sample to yield a target cDNA for further reduction in time and effort in carrying out an assay.

The use of RNA also permits microarrays of the present invention to be reused simply by washing them at a suitable temperature with a weak base solution 10 comprising, for example, 0.05 M sodium hydroxide. The base solution denatures and purges the hybridized target RNA from the microarray without damaging the DNA probes or leaving any nucleic residue that can generate background noise in subsequent assays. The preferred range for the washing temperature is from about 50° to 60°C.

15

With reference to Figure 2, the method for one embodiment of the present invention generally comprises hybridizing an RNA target sample having a polyadenylated 3' end to a complementary 5'-dendrimer poly dT capture sequence to form a pre-hybridized RNA/dendrimer complex. The pre-hybridized RNA/dendrimer 20 complex subsequently contacts the microarray, comprising multiple features each containing a specific nucleic acid sequence, typically in the form of a cDNA fragment. The RNA molecule hybridizes with the complementary cDNA at a particular feature. The microarray is washed to purge any unhybridized dendrimers that may obscure the signal detection of the hybridized RNA/cDNA and the resulting hybridization

pattern. The hybridized RNA/cDNA microarray is then scanned using any suitable commercially available microarray scanner.

In the present invention, the target nucleic acid generally comprising an RNA

5 derived from a naturally occurring source, the RNA may be selected from total RNA, poly(A)⁺ RNA, amplified RNA and the like. The initial RNA source may be present in a variety of different samples, where the sample will typically be derived from a physiological source. The physiological source may be derived from a variety of eukaryotic sources, with physiological sources of interest including sources derived

10 from single celled organisms such as yeast and multi-cellular organisms, including plants and animals, particularly mammals, where the physiological sources from multi-cellular organisms may be derived from particular organs or tissues of the multi-cellular organism, or from isolated cells derived therefrom.

15 In obtaining the sample RNAs to be analyzed, the physiological source may be subjected to a number of different processing steps, where such known processing steps may include tissue homogenation, cell isolation and cytoplasmic extraction, nucleic acid extraction and the like. Methods of isolating RNA from cells, tissues, organs or whole organisms are known to those of ordinary skill in the art and

20 are described, for example, in Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, 1989, and in Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., 1998, the content of each are incorporated herein by reference.

More preferably, the target nucleic acid is a polyadenylated RNA (poly(A)+ RNA). The poly(A)+ RNA includes an oligonucleotide which is comprised of a strand of adenine bases, or poly dA sequence, and provides a hybridization site for a dendrimer having a complementary oligonucleotide which is comprised of a strand of thymine bases, or poly dT sequence. By utilizing a poly(A)+ RNA and a dendrimer with a poly dT sequence, an RNA/dendrimer complex can be readily formed under suitable hybridization conditions. The RNA then binds to a complementary cDNA on the microarray under suitable hybridization conditions.

It is noted that poly(A)+ RNA is typically present in most genomic samples and in all genomic samples of mammalian origin such as from humans, mice, rats, pigs and the like. The present invention may also be used in conjunction with non-poly(A)+ RNA samples as well. Such non-poly(A)+ RNA lacks a poly dA sequence useful as a capture sequence in the present invention. Accordingly, such non-poly(A)+ RNA is prepared by attaching or ligating a capture sequence prior to contact with the dendrimer or the microarray.

In one embodiment of the present invention, a suitable capture sequence may be ligated to the RNA using conventional methods of splicing RNA such as through enzymatic means. Such suitable capture sequences may include poly dA sequences or customized nucleic acid sequences that are attached through methods known to those of ordinary skill in the art. Typically, a ligase enzyme can be suitably employed to splice two oligonucleotides or RNA strands to one another, or covalently couple a synthetic sequence to the end of the RNA. In the alternative, if the RNA

includes a specific oligonucleotide that is useful as a capture sequence, a complementary oligonucleotide may be attached to the dendrimer for carrying out the goals of the present invention. In a preferred embodiment, the non-poly(A)+ RNA is ligated to a poly dA sequence through the use of an enzyme capable of 5 forming an oligonucleotide of adenine bases onto the RNA strand. Such an enzyme may include poly-ADP-ribose polymerase. Either of these methods is particularly desirable in the event that the RNA sample of choice does not have an appropriate capture sequence required to carry out the methods of the present invention. The enzymatic processes as mentioned above can readily be performed by those of 10 ordinary skill in the art.

In the present invention, the capture sequence of the present invention may be further adapted to include modified nucleotides comprising locked nucleic acids (LNA) for increasing the nucleotide melt or annealing temperature attributes of the 15 corresponding annealed capture sequences to above that normally associated with standard unmodified sequences. During hybridization process, there is the prospect that the bonding between the capture sequences of the dendrimer and the RNA may be fragile due to low melt temperature attributes especially when hybridized at higher than optimal temperatures. By including such modified higher melt temperature 20 nucleotides, a stronger annealing bond is formed for a durable and permanent hybridization between complementary nucleotides. Oligonucleotides containing LNA modified nucleotides obey the Watson-Crick base pairing rules and hybridize to complementary oligonucleotides. However, LNA oligonucleotides demonstrate an improved hybridization performance. LNA/DNA and LNA/RNA duplexes are more

thermally stable and demonstrate a 3° to 8°C increase in thermal stability per modified base. Locked nucleic acids are a novel class of nucleic acid analogues that have the furanose ring of the nucleotide modified to contain methylene linker that connects the 2'-oxygen position to the 4'-carbon position thus altering the DNA backbone and stabilizing nucleic acid duplexes. Such LNA modified nucleotides may include, but not limited to, peptide nucleic acids and the like. Synthetic oligonucleotides containing LNA nucleotides are available from PROLOGO (Boulder, CO). In one embodiment of this invention, the poly dT sequence may be synthesized to contain LNA (Locked Nucleic Acid) thymidine nucleotides (LNA-T) at several positions. In this embodiment dendrimer reagents prepared using LNA modified poly dT would have the beneficial effect of increase thermal stability of hybridization between the poly A capture sequence of the RNA and the locked nucleic acid comprising thymine base (LNA-T) sequence on the labeled dendrimers preferably preventing the exchange of dendrimers from one RNA target to another.

15

In a preferred embodiment of the present invention, the dendrimers are hybridized with a poly (A)+ RNA under suitable conditions, and allowed to bind to the 5' end of the RNA via a capture sequence comprising an oligonucleotide of poly dT units. The RNA/dendrimer complexes are then hybridized to the microarray between the RNA and the complementary cDNA located at a particular feature, and the unbound dendrimers are then washed off. The dendrimers pre-labeled with a cyanine dye such as Cy3 or Cy5 are sensitive detection reagents especially suitable for high-density DNA microarrays.

Once the RNA/dendrimer complexes are formed, blocking nucleic acids or reagents including, but not limited to, dA and/or dT oligonucleotides, may be added as blocking nucleic acids or reagents to prevent unwanted hybridization which may generate "false positives". Such blocking nucleic acids are comprised of short segments complementary to the capture sequences on the dendrimers and the target RNA, respectively. The addition of blocking nucleic acids specifically prevents binding of excess dendrimers to certain features on the microarray that may contain short segments of poly dA or sequences complementary to the capture sequence on the dendrimer that may undesirably generate non-specific hybridizations. It is further desirable to add the blocking nucleic acids to the pre-hybridized RNA/dendrimer, thus preventing any exchange of dendrimers from one target RNA to another. Such blocking nucleic acids may range from about 15 to 200 base units. A preferred amount of the blocking nucleic acid may range from about 0.1 to 10 micrograms to every microgram of RNA sample used for assay. It may also be desirable to add an amount of yeast tRNA in order help protect the RNA from degradation during subsequent hybridization of the RNA to the microarray.

In order to maintain the target RNA in an intact and stable condition suitable for detection and assay, it is further preferable to add a nuclease inhibitor more preferably a ribonuclease inhibitor to protect the target RNA during the hybridization steps. An RNA preserving solution such as RNA SECURE® (available from AMBION, Austin, TX) may also be added to the target RNA for substantially reducing the rate of decomposition and degradation of the target RNA.

In performing the methods of the present invention, a quantity of poly(A)+ RNA with a polydA capture sequence, is hybridized with dendrimers with an oligonucleotide complementary to the RNA capture sequence (i.e. poly dT). The capture sequences and the complement have sufficient base units to irreversibly hybridize under suitable conditions including time and temperature sufficient for promoting the hybridization of the dendrimer to the target RNA as known by those of ordinary skill in the art. Suitable hybridization conditions are disclosed in Maniatis et al., where conditions may be modulated to achieve a desired specificity in hybridization. It is further noted that any suitable hybridization buffers may be used in the present invention. The preferred range for the first hybridization temperature is from about 45° to 60°C, more preferably 55°C. The mixture is incubated for a time from about 15 minutes to 24 hours, preferably from about 15 minutes to 16 hours, more preferably from about 15 to 20 minutes to allow the target RNA to hybridize with the dendrimers to yield a prehybridization mixture.

15

The pre-hybridization mixture is added to the microarray and incubated at a second hybridization temperature and for a time sufficient to permit the RNA to bind to the microarray. The prehybridization mixture and the microarray are incubated at the second hybridization temperature from about 15 minutes to 24 hours, preferably from about 2 to 16 hours in a humidified chamber. The preferred range for the second hybridization temperature is from about 60° to 65°C for microarrays prepared with gene probes derived from cDNAs, and from about 45° to 55°C for microarrays prepared from gene probes derived from oligonucleotides. The temperatures provided above may be adjusted in order to suit the requirements

necessary to ensure complete hybridization to a selected microarray and can be suitably determined by those of ordinary skill in the art.

Following the hybridization step, where non-hybridized dendrimers are
5 capable of emitting a signal during the detection step, a washing step is employed to
purge the non-hybridized complexes from the microarray, thus leaving behind a
visible, discrete pattern of hybridized RNA-dendrimers bound to the microarray. A
variety of wash solutions and protocols for their use are known to those of skill in the
art and may be used. The specific wash conditions employed will necessarily
10 depend on the specific nature of the signal producing system that is employed, and
will be known to those of skill in the art familiar with the particular signal producing
system employed.

The resultant hybridization pattern of labeled RNA fragments may be
15 visualized or detected in a variety of ways, with the particular manner of detection
being chosen based on the particular label of the dendrimer used in the present
invention, where representative detection systems include scintillation counting,
autoradiography, fluorescence measurement, calorimetric measurement, light
emission measurement and the like.

20

Following hybridization and any washing step(s) and/or subsequent
treatments, as described above, the resultant hybridization pattern is detected. In
detecting or visualizing the hybridization pattern, the intensity or signal value of the
label may be qualitatively and/or quantitatively detected.

Following detection or visualization, the hybridization pattern can be used to determine qualitative and/or quantitative information about the genetic profile of the labeled target nucleic acid sample that was contacted with the microarray to 5 generate the hybridization pattern, as well as the physiological source from which the labeled target nucleic acid sample was derived. From this data, one can also derive information such as the types of genes expressed in the tissue or cell that is the physiological source, as well as the levels of expression of each gene. Where one uses the subject methods in comparing target nucleic acid from two or more 10 physiological sources, the hybridization patterns may be compared to identify differences between the patterns. With microarrays in which each of the different probes corresponds to a known gene is employed, any discrepancies can be related to a differential expression of a particular gene in the physiological sources being compared. Thus, the subject methods find use in differential gene expression 15 assays, where one may use the subject methods in the differential expression analysis of: diseased and normal tissue, e.g. neoplastic and normal tissue; different tissue or subtissue types; and the like.

The forgoing discussion discloses and describes merely exemplary 20 embodiments of the present invention. One skilled in the art will readily recognize from such discussion, and from the accompanying claims, that various changes, modifications, and variations can be made therein without departing from the spirit and scope of the invention as defined in the following claims.

EXAMPLE 1

A method for determining the presence of a specific sequence of nucleotides in a nucleic acid target molecule sample on a microarray is described below.

5

Microarray Preparation

The microarray was prepared by spotting 1,700 amplified cDNAs on a sialylated glass slide (Cell Associates) using a microarrayer (Cartesian Technologies), after which the cDNA was ultraviolet (UV) cross-linked onto the slide surface with a Stratalinker (Stratagene).

10

Preparation and Concentration of Target Nucleic Acid Sequences Sample

15

The target nucleic acid sequences were prepared as total RNA extracted from a sample of cells using standard methods. For this particular example the portion of the total RNA population comprising that to be known as poly(A)+ RNA also commonly referred to as messenger RNA (mRNA) was used as the specific target sample. The sequence comprising an oligonucleotide of single adenine bases of the RNA served as the desired capture sequence.

Preparation of the Labeled Dendrimers

Dendrimers were assembled from seven oligonucleotides, strands 1–7. The seven strands were pairwise hybridized in T_{50} N_{200} E_{10} 8 buffer (T_{50} N_{200} E_{10} 8: 50 mM Tris-HCl, pH 8.0, 10 mM EDTA, and 200 mM NaCl) to form five building block “monomers”: A, B’,B”,C’, and C”. Strand 1 and strand 2 were hybridized to form the “A” monomer. Similarly, strand 3 was hybridized to strand 4 and strand 4 was hybridized to strand 5 to produce the B’ and B” monomers, respectively. The C’ monomer was prepared by hybridizing strand 2 and strand 6, and the C” monomer was prepared by hybridizing strand 2 and strand 7. Each monomer is composed of four 31-nucleotide single-stranded arms and one central 50-base waist. From these building blocks the core dendritic structure was assembled.

Dendrimer core assembly was accomplished by hybridizing one initiating A monomer with two B’ and two B” monomers in T_{50} N_{200} E_{10} 8 buffer for 20 min at 42°C to form the 1-layer dendrimer. A second layer of C’ and C” monomers was added to the one-layer assembly to form a two-layer dendrimer regenerating the original sequences present on the A monomer. Three- and four-layer dendrimers were prepared by the sequential addition of B’ and B” monomers followed by C’ and C” monomers. At each layer of assembly 4,5’,8-trimethylpsoralen (trioxsalen) was used to covalently cross-link the dendritic structure. This was accomplished by adding 1/15 of a volume of a trioxsalen-saturated ethanol solution to the hybridization mixture.

After 20 min of incubation, the hybridization mixture was cross-linked in a UV photochemical reaction chamber (model HRI100, Simms Instruments) for 10 min at 42°C. After the forth layer of assembly, the four-layer dendritic core was purified using ultracentrifugation on 10–50% sucrose gradients containing 50% deionized 5 formamide run at 40°C. Gradient fractions containing four-layer dendrimer were pooled, ethanol precipitated, and resuspended in 50 mM Tris-HCl, pH 8.0, 10 mM EDTA.

To prepare fluorescent-labeled dendrimers, a synthetic dT70 sequence was 10 ligated to the purified dendritic core material. Thirty-nucleotide-long oligonucleotides complementary to the outer arms of the four-layer dendrimer, and having a Cy3-, Cy5-, or other equivalent desirable label at the 5' end, were synthesized (Oligos Etc.). In one embodiment for single channel analysis dT70 containing core material was placed into one separate container and Cy3-linked oligonucleotides were 15 hybridized and covalently cross-linked to the outer surface of the dendrimer material. In a second embodiment for dual channel analysis the dT70 containing core material was split into two separate containers/populations. The Cy3-linked and Cy5-linked oligonucleotides were hybridized and covalently cross-linked to the outer surface of the two dendrimer populations, separately thus producing one dendrimer reagent 20 having an oligo dT70 associated with Cy3 label and a second separate reagent having an oligo dT70 associated with a Cy5 label. In a third embodiment for three or more channel analysis the dT70 containing core material was split into the respective number of containers/populations. As in the dual channel reagents labeled oligonucleotides were added to the appropriate population, hybridized and cross-

linked as separate reagents thus producing three or more different reagents each being unique as defined by the associated label.

Any excess capture and fluorescent oligonucleotides were removed by size
5 exclusion chromatography. The concentration of dendrimer was determined by
measuring the optical density of the purified material at 260 nm on a
spectrophotometer. The fluorescence was measured at the optimal signal/noise
wavelengths using a fluorometer (FluoroMax, SPEX Industries). Cy3 was excited at
542 nm, and the emission was measured at 570 nm. Cy5 was excited at 641 nm,
10 and the emission was measured at 676 nm.

Hybridization of RNA to Labeled Dendrimers

An RNA hybridization buffer was prepared with the following formulation:
15 4.5% sodium dodecyl sulfate, 200 mM sodium chloride, and 0.1M sodium
phosphate. The RNA hybridization buffer was thawed and resuspended by heating
to 65°C for ten to twelve minutes. The buffer was mixed by inversion to ensure that
the components were re-suspended evenly. The heating and mixing was repeated
until all of the material was re-suspended. The RNA was resuspended in 5.0 μ L of
20 the hybridization buffer.

In a first embodiment, single channel analysis, 2.5 μ L of one type of the
labeled dendrimers (Cy3 or Cy5) were added to the re-suspended RNA along with
12.5 μ L of the RNA hybridization buffer. In an alternative embodiment, for dual

channel analysis, 2.5 μ l of two types of the labeled dendrimers with Cy3 and Cy5, respectively, were added to the re-suspended RNA along with 10 μ L of the RNA hybridization buffer. In a further embodiment of multiple channel analysis (with three or more channels), 2.5 μ l of three or more types of the labeled dendrimers 5 comprising Cy3, Cy5, and one or more prepared using another label moiety, respectively, were added to the re-suspended RNA along with 10 μ L of the RNA hybridization buffer.

For larger hybridization buffer volumes, additional RNA hybridization buffer 10 may be added to the required final volume. It is noted that hybridization buffer volumes greater than 35 μ L may also require additional amounts of the labeled dendrimers.

The RNA hybridization buffer mixture was incubated at 55°C for 15 to 20 15 minutes to allow for pre-hybridization of the RNA to the labeled dendrimers. In one embodiment where dual or multiple channel analysis was implemented, an amount of about 2 micrograms of oligo dT70 was added to the pre-hybridized RNA/dendrimer mixtures to prevent the exchange of dendrimers between the RNA.

20 The pre-hybridized mixture was added to the microarray and then incubated from 2 hours to overnight at 55°C in a humidified chamber at a temperature from about 60° to 65°C for microarrays prepared from cDNA and from about 45° to 55°C for microarrays prepared from oligonucleotides. At this stage, the RNA was hybridized to the gene probes.

Post Hybridization Wash

The microarray was briefly washed to remove any excess labeled dendrimers. First, the microarray was washed for 10 minutes at 55° C with 2X SSC buffer, 0.2% 5 SDS. Then the microarray was washed for 10 minutes at room temperature with 2X SSC buffer. Finally the microarray was washed for 10 minutes at room temperature with 0.2X SSC buffer.

Signal Detection

10

The microarray was then scanned using a confocal laser scanner (ScanArray 3000 available from GSI Lumonics). The signal and background signals were detected and quantified using ImageQuant quantification software. Signals were measured as the means pixel intensity within each circumscribed feature, average 15 background was measured using the mean pixel intensities of blank features (no gene probe) in the microarray and as the means pixel intensity outside the circumscribed feature diameter for calculating specific signals.